Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson’s disease

Daisuke Doi; Hiroaki Magotani; Tetsuhiro Kikuchi; Megumi Ikeda; Satoe Hiramatsu; Kenji Yoshida; Naoki Amano; Masaki Nomura; Masafumi Umekage; Asuka Morizane; Jun Takahashi

doi:10.1038/s41467-020-17165-w

Nature Communications (Jul 2020)

Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson’s disease

Daisuke Doi,
Hiroaki Magotani,
Tetsuhiro Kikuchi,
Megumi Ikeda,
Satoe Hiramatsu,
Kenji Yoshida,
Naoki Amano,
Masaki Nomura,
Masafumi Umekage,
Asuka Morizane,
Jun Takahashi

Affiliations

Daisuke Doi: Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University
Hiroaki Magotani: Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University
Tetsuhiro Kikuchi: Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University
Megumi Ikeda: Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University
Satoe Hiramatsu: Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University
Kenji Yoshida: Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University
Naoki Amano: Facility for iPS Cell Therapy, Center for iPS Cell Research and Application, Kyoto University
Masaki Nomura: Facility for iPS Cell Therapy, Center for iPS Cell Research and Application, Kyoto University
Masafumi Umekage: Facility for iPS Cell Therapy, Center for iPS Cell Research and Application, Kyoto University
Asuka Morizane: Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University
Jun Takahashi: Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University

DOI: https://doi.org/10.1038/s41467-020-17165-w
Journal volume & issue: Vol. 11, no. 1
pp. 1 – 14

Abstract

Read online

Induced pluripotent stem cell (iPSC) derived dopaminergic neurons are a promising source for cell-based Parkinson’s disease (PD) therapy. Here the authors report a comprehensive pre-clinical evaluation of the safety and efficacy of dopaminergic progenitors derived from a clinical-grade human iPSC line.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal